<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04609345</url>
  </required_header>
  <id_info>
    <org_study_id>CT20-004</org_study_id>
    <nct_id>NCT04609345</nct_id>
  </id_info>
  <brief_title>Prevalence of Ocular Surface Disease in Malaysian Glaucoma Patients</brief_title>
  <official_title>Prevalence of Ocular Surface Disease in Malaysian Glaucoma Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Santen Pharma Malaysia Sdn Bhd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Santen Pharma Malaysia Sdn Bhd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, multi-centre, cross sectional observational study to determine the&#xD;
      prevalence of ocular surface disease (OSD) in glaucoma patients, nationwide. The study also&#xD;
      analyses sub group of OSD prevalence, stratified according to the treatment types (i.e.&#xD;
      preserved, preservative-free, and combination of preservative-free and preserved eyedrops),&#xD;
      and illustrates the patient perspective on OSD.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      For this prospective, multi-centre, cross sectional observational study, patients who attend&#xD;
      routine eye examination at the medical institutions and who have been diagnosed with primary&#xD;
      open-angle glaucoma, primary angle-closure glaucoma, pseudoexfoliation glaucoma, pigment&#xD;
      dispersion glaucoma or ocular hypertension will be studied. The medical institutions are&#xD;
      selected across different regions of Malaysia to assess the nationwide prevalence of OSD in&#xD;
      glaucoma patients. The routine assessments include Corneal Evaluation, Tear Break-Up Time&#xD;
      (TBUT), Hyperemia and Schirmer's test whereby the data from these assessments will be&#xD;
      collected and analyzed. The study will also includes Symptom Evaluation and Questionnaire&#xD;
      feedback.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2020</start_date>
  <completion_date type="Anticipated">May 2021</completion_date>
  <primary_completion_date type="Anticipated">April 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Fluorescein staining score (NEI/I)</measure>
    <time_frame>1 day</time_frame>
    <description>The fluorescein stained area of the cornea and conjunctiva will be measured according to the National Eye Institute/Industry (NEI/I) method.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tear Break-Up Time (TBUT)</measure>
    <time_frame>1 day</time_frame>
    <description>The time (in seconds) until the tear film breaks and the corneal surface is exposed will be measured using a slitlamp microscope.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hyperemia score</measure>
    <time_frame>1 day</time_frame>
    <description>Bulbar and palpebral conjunctiva will be examined using the reference photographs and a 4-step scale. This 4-step scale is cited from the clinical evaluation criteria of Japanese Guideline for Allergic Conjunctival Diseases.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Schirmer's score</measure>
    <time_frame>1 day</time_frame>
    <description>The test allows the water in tears to travel along the length of a paper test strip.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Symptom Evaluation</measure>
    <time_frame>1 day</time_frame>
    <description>Subjects will be evaluated for the presence of symptoms such as irritation/burning/stinging, foreign body sensation, tearing, itching and dry eye sensation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Questionnaire feedback</measure>
    <time_frame>1 day</time_frame>
    <description>Ocular Surface Disease Index (OSDI) patient questionnaire, Glaucoma QOL-15 questionnaire and Patient Experience Questionnaire (PEQ)</description>
  </secondary_outcome>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Primary Open-angle Glaucoma</condition>
  <condition>Primary Angle-Closure Glaucoma</condition>
  <condition>Pseudoexfoliation Glaucoma</condition>
  <condition>Pigment Dispersion Glaucoma</condition>
  <condition>Ocular Hypertension</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who attend routine eye examination at the medical institutions will be studied.&#xD;
        The medical institutions are selected across different regions of Malaysia to assess the&#xD;
        nationwide prevalence of OSD in glaucoma patients.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1) Age of 21 years or older and those who can provide informed consent.&#xD;
&#xD;
          -  2) On anti-glaucoma medications for &gt;6 months&#xD;
&#xD;
          -  3) IOP ≤ 21 mm Hg in the study eye at the screening examination (under treatment)&#xD;
&#xD;
          -  4) If only one eye is eligible, it is to be evaluated. If both eyes are eligible, then&#xD;
             the eye with a higher NEI score will be selected for evaluation.&#xD;
&#xD;
          -  5) A best-corrected visual acuity score of 6/36 on the Snellen Chart, or better in&#xD;
             each eye.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1) Those with secondary ocular hypertension or glaucoma&#xD;
&#xD;
          -  2) Those with severe visual field disorder (mean deviation of 20 dB or worse)&#xD;
&#xD;
          -  3) Those with a history of ocular surgeries (intraocular surgery including ocular&#xD;
             laser treatment which may affect the patient's ocular surface condition) within 6&#xD;
             months prior to the study initiation.&#xD;
&#xD;
          -  4) Those with a history of glaucoma surgery&#xD;
&#xD;
          -  5) Those with a history of corneal refractive surgery&#xD;
&#xD;
          -  6) Those with severe dry eye associated with systemic disorders, or in need of drugs&#xD;
             to treat dry eye&#xD;
&#xD;
          -  7) Those with ocular allergy, ocular infection or ocular inflammation&#xD;
&#xD;
          -  8) Those using eye drops for other ocular comorbidities&#xD;
&#xD;
          -  9) Those who need to use systemic or ophthalmic steroids (excluding topical skin&#xD;
             steroidal ointment)&#xD;
&#xD;
          -  10) Female patients who are pregnant, nursing or lactating&#xD;
&#xD;
          -  11) Those who use contact lenses&#xD;
&#xD;
          -  12) Any corneal abnormality or other corneal comorbidity condition preventing reliable&#xD;
             applanation tonometry&#xD;
&#xD;
          -  13) Those on oral antihistamine, antipsychotic or anti-depressant drugs.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eng Hui Gan, Specialist</last_name>
    <role>Principal Investigator</role>
    <affiliation>International Specialist Eye Centre (ISEC)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dr. Gan</last_name>
    <phone>603-22848989</phone>
    <email>ganenghui@yahoo.com.my</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Veni</last_name>
    <phone>603-22763333</phone>
    <email>veni.venusha.sakti@santen.com</email>
  </overall_contact_backup>
  <link>
    <url>https://www.aao.org/image/neiindustry-grading-system</url>
    <description>American Academy of Ophthalmology</description>
  </link>
  <reference>
    <citation>Harasymowycz P, Birt C, Gooi P, Heckler L, Hutnik C, Jinapriya D, Shuba L, Yan D, Day R. Medical Management of Glaucoma in the 21st Century from a Canadian Perspective. J Ophthalmol. 2016;2016:6509809. Epub 2016 Nov 8. Review.</citation>
    <PMID>27895937</PMID>
  </reference>
  <reference>
    <citation>Jonas JB, Aung T, Bourne RR, Bron AM, Ritch R, Panda-Jonas S. Glaucoma. Lancet. 2017 Nov 11;390(10108):2183-2193. doi: 10.1016/S0140-6736(17)31469-1. Epub 2017 May 31. Review.</citation>
    <PMID>28577860</PMID>
  </reference>
  <reference>
    <citation>Pérez-Bartolomé F, Martínez-de-la-Casa JM, Arriola-Villalobos P, Fernández-Pérez C, Polo V, García-Feijoó J. Ocular Surface Disease in Patients under Topical Treatment for Glaucoma. Eur J Ophthalmol. 2017 Nov 8;27(6):694-704. doi: 10.5301/ejo.5000977.</citation>
    <PMID>28497458</PMID>
  </reference>
  <reference>
    <citation>Mathews PM, Ramulu PY, Friedman DS, Utine CA, Akpek EK. Evaluation of ocular surface disease in patients with glaucoma. Ophthalmology. 2013 Nov;120(11):2241-8. doi: 10.1016/j.ophtha.2013.03.045. Epub 2013 May 25.</citation>
    <PMID>23714318</PMID>
  </reference>
  <reference>
    <citation>Saade CE, Lari HB, Berezina TL, Fechtner RD, Khouri AS. Topical glaucoma therapy and ocular surface disease: a prospective, controlled cohort study. Can J Ophthalmol. 2015 Apr;50(2):132-6. doi: 10.1016/j.jcjo.2014.11.006.</citation>
    <PMID>25863853</PMID>
  </reference>
  <reference>
    <citation>Inoue K. Managing adverse effects of glaucoma medications. Clin Ophthalmol. 2014 May 12;8:903-13. doi: 10.2147/OPTH.S44708. eCollection 2014. Review.</citation>
    <PMID>24872675</PMID>
  </reference>
  <reference>
    <citation>Ramli N, Supramaniam G, Samsudin A, Juana A, Zahari M, Choo MM. Ocular Surface Disease in Glaucoma: Effect of Polypharmacy and Preservatives. Optom Vis Sci. 2015 Sep;92(9):e222-6. doi: 10.1097/OPX.0000000000000542.</citation>
    <PMID>25730335</PMID>
  </reference>
  <reference>
    <citation>Garcia-Feijoo J, Sampaolesi JR. A multicenter evaluation of ocular surface disease prevalence in patients with glaucoma. Clin Ophthalmol. 2012;6:441-6. doi: 10.2147/OPTH.S29158. Epub 2012 Mar 22.</citation>
    <PMID>22536034</PMID>
  </reference>
  <reference>
    <citation>Ogawa Y, Kim SK, Dana R, Clayton J, Jain S, Rosenblatt MI, Perez VL, Shikari H, Riemens A, Tsubota K. International Chronic Ocular Graft-vs-Host-Disease (GVHD) Consensus Group: proposed diagnostic criteria for chronic GVHD (Part I). Sci Rep. 2013 Dec 5;3:3419. doi: 10.1038/srep03419.</citation>
    <PMID>24305504</PMID>
  </reference>
  <reference>
    <citation>Sencanic I, Gazibara T, Dotlic J, Stamenkovic M, Jaksic V, Bozic M, Grgurevic A. Validation of the Glaucoma Quality of Life-15 Questionnaire in Serbian language. Int J Ophthalmol. 2018 Oct 18;11(10):1674-1684. doi: 10.18240/ijo.2018.10.16. eCollection 2018.</citation>
    <PMID>30364180</PMID>
  </reference>
  <reference>
    <citation>Takamura E, Uchio E, Ebihara N, Ohno S, Ohashi Y, Okamoto S, Kumagai N, Satake Y, Shoji J, Nakagawa Y, Namba K, Fukagawa K, Fukushima A, Fujishima H; Japanese Society of Allergology. Japanese guideline for allergic conjunctival diseases. Allergol Int. 2011 Mar;60(2):191-203. doi: 10.2332/allergolint.11-RAI-0335. Review.</citation>
    <PMID>21636966</PMID>
  </reference>
  <reference>
    <citation>Masumoto H, Tabuchi H, Yoneda T, Nakakura S, Ohsugi H, Sumi T, Fukushima A. Severity Classification of Conjunctival Hyperaemia by Deep Neural Network Ensembles. J Ophthalmol. 2019 Jun 2;2019:7820971. doi: 10.1155/2019/7820971. eCollection 2019.</citation>
    <PMID>31275636</PMID>
  </reference>
  <reference>
    <citation>Chan EW, Li X, Tham YC, Liao J, Wong TY, Aung T, Cheng CY. Glaucoma in Asia: regional prevalence variations and future projections. Br J Ophthalmol. 2016 Jan;100(1):78-85. doi: 10.1136/bjophthalmol-2014-306102. Epub 2015 Jun 25. Review.</citation>
    <PMID>26112871</PMID>
  </reference>
  <reference>
    <citation>Holly FJ, Lamberts DW, Esquivel ED. Kinetics of capillary tear flow in the Schirmer strip. Curr Eye Res. 1982;2(1):57-70.</citation>
    <PMID>7128183</PMID>
  </reference>
  <reference>
    <citation>Miyake H, Kawano Y, Tanaka H, Iwata A, Imanaka T, Nakamura M. Tear volume estimation using a modified Schirmer test: a randomized, multicenter, double-blind trial comparing 3% diquafosol ophthalmic solution and artificial tears in dry eye patients. Clin Ophthalmol. 2016 May 13;10:879-86. doi: 10.2147/OPTH.S105275. eCollection 2016.</citation>
    <PMID>27257372</PMID>
  </reference>
  <reference>
    <citation>Bourne RRA, Kaarniranta K, Lorenz K, Traverso CE, Vuorinen J, Ropo A. Changes in ocular signs and symptoms in patients switching from bimatoprost-timolol to tafluprost-timolol eye drops: an open-label phase IV study. BMJ Open. 2019 Apr 2;9(4):e024129. doi: 10.1136/bmjopen-2018-024129.</citation>
    <PMID>30944129</PMID>
  </reference>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 20, 2020</study_first_submitted>
  <study_first_submitted_qc>October 25, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 30, 2020</study_first_posted>
  <last_update_submitted>October 25, 2020</last_update_submitted>
  <last_update_submitted_qc>October 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>International Specialist Eye Centre</investigator_affiliation>
    <investigator_full_name>Dr. Gan Eng Hui</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
    <mesh_term>Ocular Hypertension</mesh_term>
    <mesh_term>Glaucoma, Angle-Closure</mesh_term>
    <mesh_term>Exfoliation Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>To be confirmed</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

